nintedanib / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
nintedanib / Generic mfg.
NINTECOR, NCT04541680: Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis

Recruiting
3
250
Europe
Nintedanib 150 MG [Ofev], Placebo, NaCl
Assistance Publique - Hôpitaux de Paris, Boehringer Ingelheim
SARS-Cov-2 Induced Pulmonary Fibrosis
10/23
07/24
NCT05065190: A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis

Completed
3
81
RoW
nintedanib, Placebo
Boehringer Ingelheim
Lung Diseases, Interstitial
04/24
05/24
NCT05285982 / 2020-005554-23: A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)

Active, not recruiting
3
54
Europe, Canada, US, RoW
Nintedanib (Ofev®)
Boehringer Ingelheim
Lung Diseases, Interstitial
07/25
08/25

Download Options